Cure pipeline advances alongside AI infrastructure momentum

The Cure and Capital signals continued to move in tandem: the global clinical pipeline now shows 21,395 active gene, cell, mRNA and SI trials, while new research signals keep arriving—13 new Cure developments in the last 24 hours. In parallel, AMD’s AI chips drove a sharp earnings rerating as data center revenue nearly doubled, with AI chips doing the heavy lifting, a reminder that compute capacity is becoming a direct enabler for faster biology, screening, and design cycles. On the science side, new methods target the bottlenecks in discovery and mechanism: FoXSight introduces a Difference-of-Gaussian–based computational pipeline for identifying weak, target-specific fragment binding, and synthetic reaction–diffusion patterning in mammalian cells advances controllable circuit design. Taken together, these are quality signals, not hype—more attempts in the clinic, more tools in the lab, and improving underlying infrastructure. The window is still open.